Combination of cationic dexamethasone derivative and STAT3 inhibitor (WP1066) for aggressive melanoma: a strategy for repurposing a phase I clinical trial drug
- 5 June 2017
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 436 (1-2) , 119-136
Abstract
Glucocorticoid, such as dexamethasone (Dex) is often used along with chemotherapy to antagonize side effects of chemotherapy. However, sustained use of DexKeywords
Funding Information
- CSIR Network Project grant (CSC0302, BSC0123)
This publication has 36 references indexed in Scilit:
- Glucocorticoid-independent Repression of Tumor Necrosis Factor (TNF) α-stimulated Interleukin (IL)-6 Expression by the Glucocorticoid ReceptorJournal of Biological Chemistry, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- A Novel Inhibitor of Signal Transducers And Activators Of Transcription 3 Activation Is Efficacious Against Established Central Nervous System Melanoma and Inhibits Regulatory T CellsClinical Cancer Research, 2008
- Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumorsInternational Journal of Cancer, 2006
- Gemcitabine and taxanes in metastatic breast cancerAnnals of Oncology, 2006
- Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosisOncogene, 2002
- Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cellsOncogene, 2001
- Functional Roles of STAT Family Proteins: Lessons from Knockout MiceStem Cells, 1999
- Crosstalk between the interleukin-6 (IL-6)-JAK-STAT and the glucocorticoid-nuclear receptor pathway: synergistic activation of IL-6 response element by IL-6 and glucocorticoidJournal of Endocrinology, 1998
- Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblastsEuropean Journal of Immunology, 1990